权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Living Donor Extended Time Outcomes (LETO) Study

活体捐赠者延长时间结果 (LETO) 研究

基本信息

批准号：
10178007
负责人：
Chi-yuan Hsu
金额：
$ 67.5万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-01 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10178007
关键词：
Address African African American American Ancillary Study Apolipoproteins Biometry Calendar Caring Cessation of life Chronic Kidney Failure Communities Data Data Analyses Donor Exclusions Donor Selection Enrollment Epidemiology European Evaluation Genes Genetic Genotype Glomerular Filtration Rate Goals Graft Survival Guidelines Health Heterozygote Home Hybrids Individual Informed Consent Kidney Kidney Diseases Kidney Failure Kidney Transplantation Knowledge Living Donors Longitudinal Studies Organ Procurements Other Genetics Outcome Outcome Study Parents Patients Persons Publishing Registries Renal function Reporting Research Research Design Research Priority Retrospective Studies Risk Safety Sampling Societies Time Transplant Recipients Transplantation Uncertainty United States National Institutes of Health Visit adverse outcome base clinical care clinical practice clinical risk clinically significant cohort cost effective design follow-up genetic risk factor genetic variant high risk improved innovation ischemic injury kidney allograft living kidney donor novel programs prospective risk variant symposium trend

项目摘要

PROJECT SUMMARY We submit this proposal titled “Living donor Extended Time Outcomes (LETO)” as an ancillary study to the newly initiated “APOL1 Long-term Kidney Transplantation Outcomes” (APOLLO) Network. The APOLLO Consortium represents the most ambitious national study addressing the implications of donor apolipoprotein L1 gene (APOL1) renal-risk variants on kidney transplant outcomes. However, the prospective design of the parent APOLLO is underpowered to assess postdonation kidney health in living donors and outcomes in recipients of their kidneys due to due to short follow-up duration and secular trends resulting in diminishing numbers of persons with 2 APOL1 renal-risk variants donating in recent calendar years. We propose a cost-effective “hybrid” study design—jointly analyzing data collected at home-based research visits together with data collected as part of clinical care (as entered into a national registry)—that will greatly increase the number of person-years of follow-up and enhance study power. We will enroll 1,100 living donors who donated from 2001-2005 to generate data that will have a major impact on the clinical practice of living kidney donation in African Americans. Our specific aims are: Aim 1: To determine in a nationally representative sample whether African American living kidney donors with 2 APOL1 renal-risk variants are at higher risk of developing clinically significant chronic kidney disease (estimated glomerular filtration rate <45 ml/min/1.73m2) approximately two decades after donation. Aim 2: To determine whether other independent (or APOL1 interactive) gene variants associate with increased risk of clinically significant chronic kidney disease (estimated glomerular filtration rate <45 ml/min/1.73m2) in African American living kidney donors. Aim 3: To determine the impact of donor APOL1 renal-risk variants and other novel genetic risk factors on graft survival and recipient outcomes in a nationally representative sample of living donor kidney transplant recipients from African American living donors.

项目总结